Feature | February 10, 2014

MRIs Predict Catheter Ablation Benefits for Atrial Fibrillation Patients

February 10, 2014 — A contrast MRI can predict which heart patients with atrial fibrillation are most likely to benefit from catheter ablation, according to a multi-center study published in the Journal of the American Medical Association.
Loyola University Medical Center had the second highest enrollment in the international study, contributing 15 percent of the patients. David Wilber, M.D., director of Loyola's Division of Cardiology and Section of Clinical Electrophysiology, is second author. First author is Nassir Marrouche, M.D. of the University of Utah School of Medicine.
Atrial fibrillation (A-fib), the most common type of arrhythmia, is caused by erratic electrical signals in the heart. When medications don't work, A-fib often can be controlled with catheter ablation. Catheter ablation does not work for all patients, however, and there has not been a reliable way to predict which ones will benefit.
Researchers enrolled 329 patients from 15 centers in the United States, Europe and Australia. Each underwent a catheter ablation. Less than 30 days before their ablations, the patients also underwent a new type of imaging test called delayed enhancement-magnetic resonance imaging (DE-MRI) of the upper chamber of the heart (left atrium). The imaging shows scarring of the wall of the left atrium, called atrial fibrosis.
Researchers excluded 69 patients because their DE-MRIs were of insufficient quality or because researchers lost track of them during follow-up. That left 260 patients. After 475 days of follow up, patients with the least amount of scarring had significantly higher ablation success rates.
The pre-ablation DE-MRIs showed the amount of scarring in the left atrium. Scarring ranged from Stage 1 (covering less than 10 percent of the atrial wall) to Stage 4 (covering more than 30 percent of the atrial wall).
After 475 days of follow up, 85 percent of patients with the least-severe Stage 1 scarring had experienced no recurrent arrhythmias. The success rate dropped to 64 percent for patients with Stage 2 scarring, 54 percent for patients with Stage 3 scarring and only 31 percent for patients with the most severe Stage 4 scarring.
"Catheter ablation is a very effective treatment for atrial fibrillation, but it can't cure everyone," Wilber said. "The findings from this study suggest there may be patients whose scarring is so advanced that ablation in its current form is much less likely to be effective as a single procedure. In such cases, patients, in consultation with their physicians, may decide to forgo ablation, or be prepared to have more than one procedure to control the arrhythmia."
Patients unlikely to benefit from ablation still could be treated with medications, and in some circumstances with pacemakers, Wilber said.
"DE-MRI enables us to look at not just the heart size and function, but also structural changes in the heart, such as fibrosis, that can better inform treatment decisions," said Mushabbar Syed, M.D., Loyola's director of cardiovascular imaging. 
The study also suggests that earlier treatment may be beneficial, since the longer a patient experiences A-fib, the more scarring the patient is likely to have. This would need to be confirmed by further studies, Wilber said.
Patients in the study also underwent DE-MRIs 90 days after their catheter ablations. These follow-up scans showed physicians how effective the ablations had been in burning troublesome scar tissue. Such findings could help guide physicians if and when additional ablations are necessary, Wilber said.
For more information: loyolamedicine.org

Related Content

St. Jude Medical, ADO II AS trial, congenital heart disease, PDA, Amplatzer Duct Occluder II AS
News | Congenital Heart| October 19, 2016
St. Jude Medical Inc. announced the launch of the ADO II AS (AMPLATZER Duct Occluder II Additional Sizes) pediatric...
Lantheus, flurpiridaz F-18, myocardial perfusion imaging, MPI, cardiac stress testing, ASNC 2016
News | Radiopharmaceuticals and Tracers| October 17, 2016
Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F...
Medtronic, FIRE AND ICE trial, Arctic Front, cryoballoon catheter ablation, radiofrequency RF ablation, study results, Asia Pacific Heart Rhythm Society Scientific Sessions
News | Ablation Systems| October 17, 2016
Medtronic plc last week unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon...
Medtronic, FDA approval, MRI, MR-conditional scanning, cardiac devices
Technology | EP Lab| October 13, 2016
Medtronic plc is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac...
transcarotid artery revascularization, TCAR Surveillance Project, Society for Vascular Surgery Patient Safety Organization, SVS PSO,
News | Stents Carotid| October 13, 2016
A surveillance project to evaluate the safety and effectiveness of transcarotid artery revascularization (TCAR) in...
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
ZipLine Medical, Zip Surgical Skin Closure, cath lab time savings, PACE study
News | EP Lab| October 10, 2016
October 10, 2016 — ZipLine Medical Inc.
Mercator MedSystems, Bullfrog Micro-Infusion Device, DANCE trial, VIVA 2016, 13-month results
News | Peripheral Arterial Disease (PAD)| October 07, 2016
Mercator MedSystems recently announced that 13-month data from the DANCE trial was presented during a late-breaking...
Keystone Heart, TriGuard Embolic Protection Device, Neuro-TAVR study, brain lesions, American Journal of Cardiology
News | Heart Valve Technology| October 03, 2016
Keystone Heart Ltd. announced data recently published in the American Journal of Cardiology demonstrating new brain...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Overlay Init